Combination of Oral Anticoagulant with Antiplatelet and All-cause Mortality in Elderly Patients with Atrial Fibrillation and Ischemic Heart Disease.

Simple item page
dc.contributor.authorLi, Shijun
dc.contributor.authorZhang, Li
dc.contributor.authorWang, Yangyu
dc.contributor.authorLi, Na
dc.contributor.authorLi, Hongjie
dc.date.accessioned2017-01-30T04:30:54Z
dc.date.available2017-01-30T04:30:54Z
dc.date.issued2016
dc.description.abstractAim: Clinicians are often face the dilemma of choosing more appropriate antithrombotic regimen, since there is no evidence regarding the role of combination of Oral Anticoagulant (OAC) and antiplatelet which played in elderly patients with Atrial Fibrillation (AF) and Ischemic Heart Disease (IHD). We therefore aimed to investigate the effect of combination of OAC and antiplatelet on all-cause mortality in elderly patients with AF and IHD. Study Design: This is a retrospective analytical study. Place and Duration of the Study: The study was conducted in Chinese PLA General Hospital, Beijing, China. Selected patients' data available for the period between 2008 and 2014 were included in this study. Methods: A total of 669 elderly patients with AF and IHD between 2008 and 2014 were included (mean age, 80.8 years; 67.5% men). The endpoint was all-cause mortality. Risk of all-cause death was examined with Kaplan-Meier analysis and adjusted Cox regression models. Results: During a median follow-up of 1.3 years, the mortality rate was 74.3% for patients with antiplatelets, 58.6% for OAC and 42.9% for combination of both, respectively. OAC and /or antiplatelet use were associated with risk of mortality (chi-square=11.03, log rank p = 0.004) using unadjusted Kaplan-Meier analysis. In overall cohort, the adjusted hazard ratios for mortality for combination of OAC and antiplatelet was 0.41 (95% CI 0.19-0.87, p = 0.019) as compared to antiplatelet use, 0.80 (95% CI 0.39-1.64, p = 0.541) as compared to OAC use. In subgroup age ≥ 75 years, the adjusted hazard ratios for mortality were 0.40 (95% CI 0.16-1.02, p = 0.054) for combination of OAC and antiplatelet as compared to antiplatelet use, 0.79 (95% CI 0.31-1.96, p = 0.605) for combination of OAC and antiplatelet as compared to OAC use, and compared to antiplatelet use, the adjusted hazard ratio for mortality were 0.51 (95% CI 0.32-0.81, p = 0.005) for OAC use. Conclusions: Combination of OAC with antiplatelet is associated with reduced all-cause mortality and OAC is better on outcome as compared to antiplatelet agents, but OAC plus antiplatelet is not superior to OAC in elderly patients with AF and IHD and in subgroup aged ≥ 75 years.en_US
dc.identifier.citationLi Shijun, Zhang Li, Wang Yangyu, Li Na, Li Hongjie. Combination of Oral Anticoagulant with Antiplatelet and All-cause Mortality in Elderly Patients with Atrial Fibrillation and Ischemic Heart Disease.British Journal of Medicine and Medical Research. 2016; 13(7): 1-9.en_US
dc.identifier.issn2231-0614
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/182586
dc.language.isoenen_US
dc.source.urihttps://www.sciencedomain.org/abstract/13120en_US
dc.subjectAntiplateleten_US
dc.subjectanticoagulanten_US
dc.subjectelderlyen_US
dc.subjectatrial fibrillationen_US
dc.subjectischemic heart diseaseen_US
dc.titleCombination of Oral Anticoagulant with Antiplatelet and All-cause Mortality in Elderly Patients with Atrial Fibrillation and Ischemic Heart Disease.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
bjmmr2016v13n7p1-9.pdf
Size:
178.03 KB
Format:
Adobe Portable Document Format
Description:
Original research article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal of Advances in Medicine and Medical Research